{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:08:47Z","timestamp":1790536127999,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chimeric antigen receptor T\u2010cell therapy (CAR T) is a novel intervention for relapsed\/refractory diffuse large B\u2010cell lymphoma (R\/R DLBCL) and other hematologic malignancies. However, it is associated with prolonged hematologic toxicity (PHT) that is unpredictable and can significantly impair patients' quality of life.\u2003Reported here is a single\u2010center experience with PHT in adult patients with R\/R DLBCL who received commercial CAR T\u2010cell therapy between March 1, 2018 and May 30, 2020. Prolonged hematologic toxicity was defined as \u2265 grade 3 neutropenia or thrombocytopenia at day +30 after CAR T\u2010cell therapy. Of the 31 patients identified, 18 patients (58%) developed PHT. Patients with PHT had a shorter 1\u2010year overall survival (OS) than patients without PHT (36% vs. 81%,\n                    <jats:italic>P<\/jats:italic>\n                    &lt;\u2009.05). There were no differences in the median time to ANC recovery for those with PHT compared to patients without PHT (16\u2009days vs. 15\u2009days). Several risk factors were identified to be associated with PHT including CRS (\n                    <jats:italic>P<\/jats:italic>\n                    =\u2009.002), receipt of tocilizumab (\n                    <jats:italic>P<\/jats:italic>\n                    =\u2009.002) or steroids (\n                    <jats:italic>P<\/jats:italic>\n                    =\u2009.033), peak ferritin &gt;5000\u2009ng\/ml (\n                    <jats:italic>P<\/jats:italic>\n                    =\u2009.048), peak C\u2010reactive protein (CRP)\u2009&gt;\u2009100\u2009mg\/L (\n                    <jats:italic>P<\/jats:italic>\n                    =\u2009.007), and ferritin greater than the upper limit of normal at day +30. Seven patients with PHT underwent a bone marrow biopsy after CAR T\u2010cell therapy; all showed complete aplasia or were hypocellular with cellularity ranging from &lt;5% to 10%. These findings identify PHT as a significant toxicity associated with CAR T\u2010cell therapy and highlight the critical need for further investigations to describe PHT in larger cohorts and identify standards for management of this condition.\n                  <\/jats:p>","DOI":"10.1002\/ajh.26113","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T11:19:59Z","timestamp":1612523999000},"page":"455-461","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies"],"prefix":"10.1002","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-3665","authenticated-orcid":false,"given":"Sarah J.","family":"Nagle","sequence":"first","affiliation":[{"name":"Knight Cancer Institute Oregon Health &amp; Science University  Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0893-1419","authenticated-orcid":false,"given":"Catherine","family":"Murphree","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute Oregon Health &amp; Science University  Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6841-4993","authenticated-orcid":false,"given":"Philipp W.","family":"Raess","sequence":"additional","affiliation":[{"name":"Department of Pathology Oregon Health &amp; Science University  Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levanto","family":"Schachter","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute Oregon Health &amp; Science University  Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Chen","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute Oregon Health &amp; Science University  Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Hayes\u2010Lattin","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute Oregon Health &amp; Science University  Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneida","family":"Nemecek","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute Oregon Health &amp; Science University  Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute Oregon Health &amp; Science University  Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2595"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127508"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_2_7_11_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 5th ed. [ebook]. Available at:https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed November 20 2020."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S136988"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2015.1025753"},{"key":"e_1_2_7_15_1","unstructured":"BMT CTN. Appendix 4\u2010A: Severity Grading Table and Recurrence Interval Definations.2013.https:\/\/web.emmes.com\/study\/bmt2\/public\/MOP\/BMT%20CTN%20Technical%20MOP%20v3.pdf."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp297"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1697814"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.311"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2009.12.001"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T22:28:28Z","timestamp":1693088908000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1002\/ajh.26113"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26113","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"2021-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}